Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alejandra M. Muñoz-Suarez"'
Autor:
Diego A. Álvarez-Díaz, Ana Luisa Muñoz, Pilar Tavera-Rodríguez, María T. Herrera-Sepúlveda, Hector Alejandro Ruiz-Moreno, Katherine Laiton-Donato, Carlos Franco-Muñoz, Dioselina Pelaez-Carvajal, Diego Cuellar, Alejandra M. Muñoz-Suarez, Marisol Galindo, Edgar J. Arias-Ramírez, Marcela Mercado-Reyes
Publikováno v:
Vaccines, Vol 10, Iss 2, p 180 (2022)
Global surveillance programs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are showing the emergence of variants with mutations in the spike protein. Genomic and laboratory surveillance are important to determine if these variants
Externí odkaz:
https://doaj.org/article/f7490f76e01e4cccabeb4b8ffaf2d633
Autor:
Diego A. Álvarez-Díaz, Ana Luisa Muñoz, María T. Herrera-Sepúlveda, Pilar Tavera-Rodríguez, Katherine Laiton-Donato, Carlos Franco-Muñoz, Héctor Alejandro Ruiz-Moreno, Dioselina Pelaez-Carvajal, Alejandra M. Muñoz-Suarez, Marisol Galindo, Jhonnatan Reales-Gonzalez, Jenssy D. Catama, Beatriz Helena De Arco, Tatiana Cobos, Edgar J. Arias-Ramirez, Marcela Mercado-Reyes
BackgroundBy March 2022, around 34 million people in Colombia had received a complete scheme of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including, mRNA-based vaccines, viral vectored coronavirus vaccines, or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::466050b6157093e7905da8756f23c808
https://doi.org/10.1101/2022.03.15.22272371
https://doi.org/10.1101/2022.03.15.22272371
Autor:
Diego A. Álvarez-Díaz, Ana Luisa Muñoz, Pilar Tavera-Rodríguez, María T. Herrera-Sepúlveda, Hector Alejandro Ruiz-Moreno, Katherine Laiton-Donato, Carlos Franco-Muñoz, Dioselina Pelaez-Carvajal, Diego Cuellar, Alejandra M. Muñoz-Suarez, Marisol Galindo, Edgar J. Arias-Ramírez, Marcela Mercado-Reyes
Publikováno v:
Vaccines. 10(2)
Global surveillance programs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are showing the emergence of variants with mutations in the spike protein. Genomic and laboratory surveillance are important to determine if these variants